CA2320040A1 - Mesenchymal stem cells for prevention and treatment of immune responses in transplantation - Google Patents

Mesenchymal stem cells for prevention and treatment of immune responses in transplantation Download PDF

Info

Publication number
CA2320040A1
CA2320040A1 CA002320040A CA2320040A CA2320040A1 CA 2320040 A1 CA2320040 A1 CA 2320040A1 CA 002320040 A CA002320040 A CA 002320040A CA 2320040 A CA2320040 A CA 2320040A CA 2320040 A1 CA2320040 A1 CA 2320040A1
Authority
CA
Canada
Prior art keywords
stem cells
mesenchymal stem
treatment
transplantation
prevention
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002320040A
Other languages
French (fr)
Other versions
CA2320040C (en
Inventor
Kevin R. Mcintosh
Joseph D. Mosca
Elena N. Klyushnenkova
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mesoblast International SARL
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2320040A1 publication Critical patent/CA2320040A1/en
Application granted granted Critical
Publication of CA2320040C publication Critical patent/CA2320040C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]

Abstract

Disclosed is a method of reducing an immune response to a transplant in a recipient by treating said recipient with an amount of mesenchymal stem cells effective to reduce or inhibit host rejection of the transplant. The mesenchymal stem cells can be administered before, at the same time as, or after the transplant. Also disclosed is a method of inducing a reduced immune response against a host by foreign tissue, i.e., graft versus host disease, by treatment with mesenchymal stem cells.
CA002320040A 1998-03-18 1999-03-12 Mesenchymal stem cells for prevention and treatment of immune responses in transplantation Expired - Lifetime CA2320040C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US7846398P 1998-03-18 1998-03-18
US60/078,463 1998-03-18
US8996498P 1998-06-19 1998-06-19
US60/089,964 1998-06-19
PCT/US1999/005548 WO1999047163A2 (en) 1998-03-18 1999-03-12 Mesenchymal stem cells for prevention and treatment of immune responses in transplantation

Publications (2)

Publication Number Publication Date
CA2320040A1 true CA2320040A1 (en) 1999-09-23
CA2320040C CA2320040C (en) 2007-05-22

Family

ID=26760560

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002320040A Expired - Lifetime CA2320040C (en) 1998-03-18 1999-03-12 Mesenchymal stem cells for prevention and treatment of immune responses in transplantation

Country Status (11)

Country Link
US (1) US6328960B1 (en)
EP (1) EP1066052B1 (en)
JP (1) JP4740452B2 (en)
AT (1) ATE316795T1 (en)
AU (1) AU755888B2 (en)
CA (1) CA2320040C (en)
DE (1) DE69929681T2 (en)
DK (1) DK1066052T3 (en)
ES (1) ES2258329T3 (en)
PT (1) PT1066052E (en)
WO (1) WO1999047163A2 (en)

Families Citing this family (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69922933T2 (en) * 1998-03-13 2005-12-29 Osiris Therapeutics, Inc. APPLICATIONS FOR HUMAN NON AUTOLOGOLOGY, MESENCHYMAL STEM CELLS
US7115417B1 (en) 1998-05-01 2006-10-03 Chancellor Michael B Soft tissue and bone augmentation and bulking utilizing muscle-derived progenito compositions, and treatments thereof
US6866842B1 (en) 1998-05-01 2005-03-15 University Of Pittsburgh Muscle-derived cells (MDCs) for treating muscle-or bone-related injury or dysfunction
US8147824B2 (en) * 1999-08-05 2012-04-03 Athersys, Inc. Immunomodulatory properties of multipotent adult progenitor cells and uses thereof
US6685936B2 (en) * 1999-10-12 2004-02-03 Osiris Therapeutics, Inc. Suppressor cells induced by culture with mesenchymal stem cells for treatment of immune responses in transplantation
PT1272204E (en) 2000-04-14 2007-10-02 Univ Pittsburgh Soft tissue and bone augmentation and bulking utilizing muscle-derived progenitor cells, compositions and treatments thereof
US7311905B2 (en) 2002-02-13 2007-12-25 Anthrogenesis Corporation Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
ES2522890T3 (en) 2000-12-06 2014-11-19 Anthrogenesis Corporation Method to collect placental stem cells
WO2002063962A1 (en) * 2001-02-14 2002-08-22 Hariri Robert J Renovation and repopulation of decellularized tissues and cadaveric organs by stem cells
IL157350A0 (en) * 2001-02-14 2004-02-19 Anthrogenesis Corp Post-partum mammalian placenta, its use and placental stem cells therefrom
WO2002067867A2 (en) 2001-02-23 2002-09-06 The University Of Pittsburgh Rapid preparation of stem cell matrices for use in tissue and organ treatment and repair
WO2003073998A2 (en) * 2002-03-02 2003-09-12 Board Of Regents, The University Of Texas System Local production and/or delivery of anti-cancer agents by stromal cell precursors
CA2521217C (en) * 2003-04-01 2013-05-14 United States Of America Department Of Veteran's Affairs Stem-cell, precursor cell, or target cell-based treatment of multi-organ failure and renal dysfunction
ES2354304T3 (en) 2003-04-25 2011-03-11 The University Of Pittsburgh CELLS DERIVED FROM THE MUSCLE (MDCS) TO PROMOTE AND POWER THE REGENERATION AND REPAIR OF NERVES.
WO2005093044A1 (en) * 2004-03-22 2005-10-06 Osiris Therapeutics, Inc. Mesenchymal stem cells and uses therefor
ATE556134T1 (en) * 2004-03-22 2012-05-15 Osiris Therapeutics Inc MESENCHYMA STEM CELLS AND USES THEREOF
US20080095749A1 (en) * 2004-03-22 2008-04-24 Sudeepta Aggarwal Mesenchymal stem cells and uses therefor
US7622108B2 (en) 2004-04-23 2009-11-24 Bioe, Inc. Multi-lineage progenitor cells
US7670596B2 (en) 2004-04-23 2010-03-02 Bioe, Inc. Multi-lineage progenitor cells
ES2264862B8 (en) * 2004-08-25 2017-01-20 Cellerix, S.L. BIOMATERIAL FOR SUTURE.
ES2313805B1 (en) 2004-10-04 2009-12-23 Cellerix, S.L. IDENTIFICATION AND ISOLATION OF MULTIPOTENT CELLS OF NON-OSTEOCONDRAL MESENQUIMAL FABRIC.
US9408876B2 (en) * 2004-09-10 2016-08-09 Cognate Therapeutics, Inc. Liver stromal cells for prevention and treatment of immune responses in transplantation
US8017395B2 (en) 2004-12-17 2011-09-13 Lifescan, Inc. Seeding cells on porous supports
CA2512667A1 (en) * 2005-01-07 2006-07-07 Takahiro Ochiya Human hepatocyte-like cells and uses thereof
BRPI0606678A2 (en) * 2005-01-11 2009-07-07 Cognate Therapeutics Inc Bone marrow stromal cells for immunoprotection of transplanted neural stem cells
US20080241112A1 (en) * 2005-05-10 2008-10-02 Christof Westenfelder Therapy of Kidney Diseases and Multiorgan Failure with Mesenchymal Stem Cells and Mesenchymal Stem Cell Conditioned Media
AU2006202209B2 (en) * 2005-05-27 2011-04-14 Lifescan, Inc. Amniotic fluid derived cells
PL1888123T3 (en) * 2005-06-08 2013-06-28 Janssen Biotech Inc A cellular therapy for ocular degeneration
KR20080105555A (en) * 2007-05-31 2008-12-04 인하대학교 산학협력단 Therapeutic agent or method for treating graft-versus-host disease using mesenchymal stem cells
FR2890976B1 (en) * 2005-09-20 2007-12-14 Univ La Reunion KIT FOR PREPARING A COMPOSITION COMPRISING ADIPOCYTE CELLS AND METHOD FOR OBTAINING THE SAME
EP1957633B1 (en) 2005-10-13 2013-12-18 Anthrogenesis Corporation Immunomodulation using placental stem cells
US11000546B2 (en) 2005-11-09 2021-05-11 Athersys, Inc. Immunomodulatory properties of MAPCs and uses thereof
US10117900B2 (en) 2005-11-09 2018-11-06 Athersys, Inc. MAPC treatment of brain injuries and diseases
US20070122448A1 (en) * 2005-11-28 2007-05-31 Alireza Rezania Compositions and methods to create a vascularized environment for cellular transplantation
EP1795588A1 (en) 2005-12-07 2007-06-13 Cellerix, S.L. Use of adipose tissue derived mesenchymal stem cells for the treatment of graft versus host disease
JP5289970B2 (en) * 2005-12-16 2013-09-11 エシコン・インコーポレイテッド Compositions and methods for inhibiting reverse immune responses in histocompatible incompatible transplants
KR20080081088A (en) 2005-12-29 2008-09-05 안트로제네시스 코포레이션 Co-culture of placental stem cells and stem cells from a second source
CN103146640B (en) 2005-12-29 2015-09-09 人类起源公司 Placental stem cell populations
US20080286249A1 (en) * 2006-01-12 2008-11-20 Varney Timothy R Use of mesenchymal stem cells for treating genetic diseases and disorders
AU2007205522B2 (en) 2006-01-13 2011-08-11 Two Cells Co., Ltd. Additive for culture medium for use in serum-free culture of animal cell, kit, and use of the additive or kit
ES2415855T3 (en) 2006-01-13 2013-07-29 Osiris Therapeutics, Inc. Mesenchymal stem cells expressing the TNF receptor
CN104027359A (en) 2006-01-23 2014-09-10 阿特西斯公司 MAPC Therapeutics Without Adjunctive Immunosuppressive Treatment
EP2019858B1 (en) 2006-04-17 2012-06-13 BioE LLC Differentiation of multi-lineage progenitor cells to respiratory epithelial cells
US8741643B2 (en) 2006-04-28 2014-06-03 Lifescan, Inc. Differentiation of pluripotent stem cells to definitive endoderm lineage
US7993918B2 (en) 2006-08-04 2011-08-09 Anthrogenesis Corporation Tumor suppression using placental stem cells
US8172784B2 (en) 2006-10-11 2012-05-08 The General Hospital Corporation Compositions, methods, and devices for treating liver disease
ES2441560T3 (en) * 2006-11-03 2014-02-05 Aastrom Biosciences, Inc. Mixed cell populations for tissue repair and separation technique for cell processing
JP5425641B2 (en) 2007-01-11 2014-02-26 ユニバーシティー オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケーション Muscle-derived cells for the treatment of urinary tract conditions and methods of making and using the same
NZ578819A (en) 2007-02-12 2012-02-24 Anthrogenesis Corp Treatment of inflammatory diseases using placental stem cells
US20100291042A1 (en) 2007-05-03 2010-11-18 The Brigham And Women's Hospital, Inc. Multipotent stem cells and uses thereof
US9080145B2 (en) 2007-07-01 2015-07-14 Lifescan Corporation Single pluripotent stem cell culture
WO2009018453A1 (en) 2007-07-31 2009-02-05 Lifescan, Inc. Differentiation of human embryonic stem cells
US20110262402A1 (en) * 2007-09-07 2011-10-27 Masahiko Kuroda Therapeutic and prophylactic agents for arthritis
ES2530995T3 (en) 2007-09-28 2015-03-09 Anthrogenesis Corp Tumor suppression using human placental perfusate and intermediate natural killer cells that come from human placenta
WO2009057537A1 (en) 2007-11-02 2009-05-07 Jcr Pharmaceuticals Co., Ltd. Pharmaceutical composition containing human mesenchymal stem cell
CN101878298B (en) * 2007-11-27 2017-08-15 生命扫描有限公司 The differentiation of human embryo stem cell
US8512696B2 (en) 2007-11-30 2013-08-20 Autologous, Llc Methods of isolating non-senescent cardiac stem cells and uses thereof
AU2008334058B2 (en) 2007-11-30 2014-07-10 New York Medical College Compositions comprising vascular and myocyte progenitor cells and methods of their use
AU2008334036B2 (en) 2007-11-30 2014-05-29 New York Medical College Methods of reducing transplant rejection and cardiac allograft vasculopathy by implanting autologous stem cells
KR101731474B1 (en) 2008-02-21 2017-05-11 얀센 바이오테크 인코포레이티드 Methods, surface modified plates and compositions for cell attachment, cultivation and detachment
JP5541845B2 (en) * 2008-03-28 2014-07-09 Ｊｃｒファーマ株式会社 Atopic dermatitis treatment
US8623648B2 (en) 2008-04-24 2014-01-07 Janssen Biotech, Inc. Treatment of pluripotent cells
US20110150845A1 (en) * 2008-05-02 2011-06-23 Massachusetts Institute Of Technology Methods and compositions for modulating immunological tolerance
RU2011103183A (en) * 2008-06-30 2012-08-10 Сентокор Орто Байотек Инк. (Us) DIFFERENTIATION OF PLURIPOTENT STEM CELLS
KR101829310B1 (en) 2008-06-30 2018-02-14 얀센 바이오테크 인코포레이티드 Differentiation of pluripotent stem cells
US20100028307A1 (en) * 2008-07-31 2010-02-04 O'neil John J Pluripotent stem cell differentiation
US8637004B2 (en) 2008-08-14 2014-01-28 Mesoblast International Sarl Purified mesenchymal stem cell compositions and methods of purifying mesenchymal stem cell compositions
US9199003B2 (en) 2008-08-18 2015-12-01 University of Pittsburgh—of the Commonwealth System of Higher Education Bone augmentation utilizing muscle-derived progenitor compositions in biocompatible matrix, and treatments thereof
US10104880B2 (en) 2008-08-20 2018-10-23 Celularity, Inc. Cell composition and methods of making the same
DK2329012T3 (en) 2008-08-20 2020-08-24 Celularity Inc Treatment of stroke using isolated placental cells
MX339068B (en) 2008-08-22 2016-05-10 Anthrogenesis Corp Methods and compositions for treatment of bone defects with placental cell populations.
MX349178B (en) 2008-10-31 2017-07-17 Centocor Ortho Biotech Inc Differentiation of human embryonic stem cells to the pancreatic endocrine lineage.
ES2634445T3 (en) 2008-10-31 2017-09-27 Janssen Biotech, Inc. Differentiation of human embryonic stem cells with pancreatic endocrine lineage
US20110212523A1 (en) 2008-11-11 2011-09-01 Yukio Kato Differentiation-inducing culture medium additive and use thereof
NZ602455A (en) 2008-11-19 2014-03-28 Anthrogenesis Corp Amnion derived adherent cells
MX356756B (en) 2008-11-20 2018-06-11 Centocor Ortho Biotech Inc Pluripotent stem cell culture on micro-carriers.
JP5719305B2 (en) * 2008-11-20 2015-05-13 ヤンセン バイオテツク，インコーポレーテツド Methods and compositions for cell attachment and culture on a planar support
GB0822246D0 (en) * 2008-12-05 2009-01-14 Reneuron Ltd Composition
GB0902034D0 (en) 2009-02-06 2009-03-11 Reneuron Ltd Method
US9301975B2 (en) 2009-05-01 2016-04-05 Biocardia, Inc. Method of preparing autologous cells and method of use for therapy
AU2010276438B2 (en) 2009-07-20 2015-06-11 Janssen Biotech Inc. Differentiation of human embryonic stem cells
RU2540021C2 (en) * 2009-07-20 2015-01-27 Янссен Байотек, Инк. Differentiating human embryonic stem cells
CN103952372B (en) 2009-07-20 2016-10-05 詹森生物科技公司 The differentiation of human embryo stem cell
DK2456853T3 (en) * 2009-07-21 2021-02-01 Abt Holding Co USE OF STEM CELLS TO REDUCE LEUCOCYT EXTRAVASATION
AU2010319921A1 (en) * 2009-10-29 2012-05-17 Janssen Biotech Inc. Pluripotent stem cells
WO2011079018A2 (en) 2009-12-23 2011-06-30 Centocor Ortho Biotech Inc. Differentiation of human embryonic stem cells
WO2011079017A2 (en) 2009-12-23 2011-06-30 Centocor Ortho Biotech Inc. Differentiation of human embryonic stem cells
US9121007B2 (en) 2010-01-26 2015-09-01 Anthrogenesis Corporatin Treatment of bone-related cancers using placental stem cells
CN102791851B (en) 2010-03-01 2017-07-14 詹森生物科技公司 The method of cell of the purifying derived from multipotential stem cell
JP5804385B2 (en) * 2010-03-10 2015-11-04 株式会社ツーセル Cell preparation containing mesenchymal stem cells and method for producing the same
KR20190076060A (en) 2010-04-07 2019-07-01 안트로제네시스 코포레이션 Angiogenesis using placental stem cells
US8562973B2 (en) 2010-04-08 2013-10-22 Anthrogenesis Corporation Treatment of sarcoidosis using placental stem cells
EP3498825A1 (en) 2010-05-12 2019-06-19 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
WO2011143415A1 (en) 2010-05-12 2011-11-17 Abt Holding Company Modulation of splenocytes in cell therapy
EP2593542B1 (en) 2010-07-13 2018-01-03 Anthrogenesis Corporation Methods of generating natural killer cells
WO2012030539A2 (en) 2010-08-31 2012-03-08 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
SG187947A1 (en) 2010-08-31 2013-03-28 Janssen Biotech Inc Differentiation of pluripotent stem cells
MX355340B (en) 2010-08-31 2018-04-16 Janssen Biotech Inc Differentiation of human embryonic stem cells.
US20120087933A1 (en) 2010-10-08 2012-04-12 Samson Tom Enhanced msc preparations
WO2012048275A2 (en) 2010-10-08 2012-04-12 Caridianbct, Inc. Configurable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system
AU2011352036A1 (en) 2010-12-31 2013-07-18 Anthrogenesis Corporation Enhancement of placental stem cell potency using modulatory RNA molecules
US9040035B2 (en) 2011-06-01 2015-05-26 Anthrogenesis Corporation Treatment of pain using placental stem cells
US20120330438A1 (en) * 2011-06-22 2012-12-27 Shaf Keshavjee Repaired organ and method for making the same
US9925221B2 (en) 2011-09-09 2018-03-27 Celularity, Inc. Treatment of amyotrophic lateral sclerosis using placental stem cells
RU2705001C2 (en) 2011-12-22 2019-11-01 Янссен Байотек, Инк. Differentiation of human embryonic stem cells into single-hormonal insulin-positive cells
JP6383292B2 (en) 2012-03-07 2018-08-29 ヤンセン バイオテツク，インコーポレーテツド Clear media for proliferation and maintenance of pluripotent stem cells
JP6193214B2 (en) 2012-03-29 2017-09-06 Ｊｃｒファーマ株式会社 Method for producing dental pulp-derived pluripotent stem cells
JP6469003B2 (en) 2012-06-08 2019-02-13 ヤンセン バイオテツク，インコーポレーテツド Differentiation of human embryonic stem cells into pancreatic endocrine cells
ES2837763T3 (en) 2012-12-31 2021-07-01 Janssen Biotech Inc Culture of human embryonic stem cells in the air-liquid interface for differentiation into pancreatic endocrine cells
US10370644B2 (en) 2012-12-31 2019-08-06 Janssen Biotech, Inc. Method for making human pluripotent suspension cultures and cells derived therefrom
BR112015015714A2 (en) 2012-12-31 2017-07-11 Janssen Biotech Inc suspension and agglomeration of human pluripotent cells for differentiation into pancreatic endocrine cells
ES2942484T3 (en) 2012-12-31 2023-06-01 Janssen Biotech Inc Differentiation of human embryonic stem cells into pancreatic endocrine cells using HB9 regulators
US9763983B2 (en) 2013-02-05 2017-09-19 Anthrogenesis Corporation Natural killer cells from placenta
CA2909267C (en) * 2013-04-12 2022-10-25 Saverio LA FRANCESCA Improving organs for transplantation
US10633625B2 (en) 2013-11-16 2020-04-28 Terumo Bct, Inc. Expanding cells in a bioreactor
ES2769778T3 (en) * 2013-12-13 2020-06-29 Swedish Stromabio Ab Immunomodulatory compositions
EP3122866B1 (en) 2014-03-25 2019-11-20 Terumo BCT, Inc. Passive replacement of media
CA2949056A1 (en) 2014-05-16 2015-11-19 Janssen Biotech, Inc. Use of small molecules to enhance mafa expression in pancreatic endocrine cells
JP6830059B2 (en) 2014-09-26 2021-02-17 テルモ ビーシーティー、インコーポレーテッド Scheduled cell feeding
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
MA45479A (en) 2016-04-14 2019-02-20 Janssen Biotech Inc DIFFERENTIATION OF PLURIPOTENT STEM CELLS IN ENDODERMAL CELLS OF MIDDLE INTESTINE
EP3464565A4 (en) 2016-05-25 2020-01-01 Terumo BCT, Inc. Cell expansion
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
MY173386A (en) * 2016-06-09 2020-01-21 Cytopeutics Sdn Bhd A cell-based composition and use thereof for treatment of vernal keratoconjunctivitis
EP3583945A4 (en) 2017-02-15 2020-11-18 Rohto Pharmaceutical Co., Ltd. Pulmonary fibrosis treatment agent, ptprr expression-promoting agent, and kit for pulmonary fibrosis treatment
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
WO2018184028A2 (en) 2017-03-31 2018-10-04 Terumo Bct, Inc. Cell expansion
JPWO2018225440A1 (en) 2017-06-09 2020-04-09 国立大学法人大阪大学 Agent for dilated cardiomyopathy
CN113677789A (en) 2019-03-12 2021-11-19 全球干细胞技术公司 Immunomodulatory mesenchymal stem cells

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5486359A (en) * 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US5733542A (en) 1990-11-16 1998-03-31 Haynesworth; Stephen E. Enhancing bone marrow engraftment using MSCS
US5591625A (en) * 1993-11-24 1997-01-07 Case Western Reserve University Transduced mesenchymal stem cells
US5759536A (en) * 1994-05-27 1998-06-02 University Technology Corporation Use of fas ligand to supress T-lymphocyte-mediated immune responses
US6006752A (en) * 1996-05-09 1999-12-28 The General Hospital Corporation Mixed chimerism and tolerance

Also Published As

Publication number Publication date
CA2320040C (en) 2007-05-22
AU755888B2 (en) 2003-01-02
WO1999047163A2 (en) 1999-09-23
EP1066052B1 (en) 2006-02-01
JP4740452B2 (en) 2011-08-03
WO1999047163A3 (en) 1999-11-18
DE69929681T2 (en) 2006-10-26
EP1066052A2 (en) 2001-01-10
JP2002506831A (en) 2002-03-05
US6328960B1 (en) 2001-12-11
AU3185699A (en) 1999-10-11
DK1066052T3 (en) 2006-06-12
DE69929681D1 (en) 2006-04-13
ATE316795T1 (en) 2006-02-15
ES2258329T3 (en) 2006-08-16
PT1066052E (en) 2006-06-30

Similar Documents

Publication Publication Date Title
CA2320040A1 (en) Mesenchymal stem cells for prevention and treatment of immune responses in transplantation
EP2269616A3 (en) Supernatant from mesenchymal stem cells for prevention and treatment of immune responses in transplantation
EP1220611A4 (en) Suppressor cells for prevention and treatment of immune responses in transplantation
CA2196165A1 (en) Methods for treating implantable biological tissues to mitigate the calcification thereof and bioprosthetic articles treated by such methods
CA2017705A1 (en) Human heart valve replacement with porcine pulmonary valve
EP0174737A3 (en) Treatment of collagenous tissue
EP0103947A3 (en) Method for inhibiting mineralization of natural tissue during implantation
CA2286655A1 (en) Tissue decellularization
AU3513395A (en) Biological material pre-fixation treatment
CA2185447A1 (en) Treated tissue for implantation and preparation methods
AU8476698A (en) Human mesenchymal stem cells from peripheral blood
ZA948299B (en) Method of making calcification-resistant bioprosthetic tissue
NZ212051A (en) Immune response suppression; certain epipolythio- dioxopiperazine derivatives and their preparation
CA2346644A1 (en) Method for preventing xenograft transplant rejection using photodynamic therapy
WO2000029002A3 (en) In utero transplantation of human mesenchymal stem cells
EA200000058A1 (en) TREATMENT THROUGH CD154 BLOCKADE UNDER TRANSPLANTATION OF PANCREATIC ISLAND TISSUES
WO2002024244A3 (en) Method of preparing and processing transplant tissue
WO2006031539A3 (en) Liver stromal cells for prevention and treatment of immune responses in transplantation
CA2089336A1 (en) Method for processing and preserving collagen-based tissues for transplantation
FRITZ THE CHARACTERIZATION OF RIBONUCLEASE ACTIVITIES FROM CULTURED MOSQUITO CELLS AND FROM MOSQUITO TISSUES DURING DEVELOPMENT.
CA2188135A1 (en) Biological material pre-fixation treatment
MX9504896A (en) Bovine pericardium treated with glutaraldehyde, as thoracoabdominal wall, pulmonary and bronchial tissue bioprosthesis.
NZ335999A (en) Composition and method for the treatment of vaginal yeast infections comprising lactobacillus cells
AU3295495A (en) Method for the treatment or prophylaxis of endo- and ectoparasitic infestations in dogs
WO2002007584A3 (en) Method for recellularization of a decellularized heart valve and heart valve produced thereby

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20190312